# Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab

> **NCT01363739** · — · UNKNOWN · sponsor: **Azienda Ospedaliero, Universitaria Pisana** · enrollment: 265 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01363739
- **Lead sponsor:** Azienda Ospedaliero, Universitaria Pisana
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 265 (ESTIMATED)
- **Last updated:** 2011-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01363739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01363739, "Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT01363739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*